Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Autoimmune Disorders

Free Subscription Articles published in Brain Retrieve available abstracts of 98 articles: HTML format

Single Articles

October 2026
1. HUNT DPJ
   Preventing autoimmunity after alemtuzumab in multiple sclerosis: regulatory T cells resist expansion.
   Brain. 2026 Oct 21:awag308. doi: 10.1093.
   PubMed    
   
   
   
2. FREEMAN SA, Liblau RS
   A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis.
   Brain. 2026 Oct 17:awag360. doi: 10.1093.
   PubMed    
   
   
   
3. UHER T, Nagels G
   Mapping brain imaging heterogeneity in multiple sclerosis.
   Brain. 2026 Oct 8:awag349. doi: 10.1093.
   PubMed    
   
   
   September 2026
4. PREZIOSA P, Storelli L, Clarelli F, Pagani E, et al
   Imaging subtypes reveal distinct biological substrates and disability profiles in multiple sclerosis.
   Brain. 2026 Sep 23:awag320. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. TYYSTJARVI S, Ruiz Navarro DE, Kulisch LM, Hartmann AH, et al
   Anti-CD40L prevents meningeal B cell aggregates and mitigates progressive autoimmune encephalomyelitis.
   Brain. 2026 Sep 16:awag274. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. FAROOQ R, Cutler B, Pisa M, Balaram Kuttikkatte S, et al
   Multimodal discovery of a pathogenic B cell-dependent T cell state in multiple sclerosis.
   Brain. 2026 Sep 9:awag303. doi: 10.1093.
   PubMed     Abstract available
   
   
   
7. BROWN JWL
   Untangling prognosis in multiple sclerosis.
   Brain. 2026;149:2909-2911.
   PubMed    
   
   
   August 2026
8. FOSTER MA, Wade C, Ford HL, Schmierer K, et al
   Diagnosing multiple sclerosis: implementation and unintended effects of the 2024 McDonald criteria.
   Brain. 2026 Aug 28:awag293. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. GRUT V, Ingvarsson J, Bistrom M, Jons D, et al
   Lytic Epstein-Barr virus infection and emerging autoantibodies precede multiple sclerosis prodrome.
   Brain. 2026 Aug 22:awag283. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. SORMANI MP, Wiendl H, Montalban X, Oh J, et al
    Rethinking multiple sclerosis therapy beyond clinical phenotypes.
    Brain. 2026 Aug 18:awag273. doi: 10.1093.
    PubMed    
    
    
    
11. DA SILVA MTT, Araujo AQC
    HTLV-1-associated myelopathy as a translational model of progressive neurodegeneration.
    Brain. 2026;149:2592-2603.
    PubMed     Abstract available
    
    
    July 2026
12. DARUWALLA C, Kremler C, Patti F, Ozakbas S, et al
    Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.
    Brain. 2026 Jul 24:awag252. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. 
    Correction to: IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology.
    Brain. 2026 Jul 13:awag229. doi: 10.1093.
    PubMed    
    
    
    
14. SANDGREN S, Leppert D, Kuhle J
    Propionic acid and neurofilament light chain in multiple sclerosis.
    Brain. 2026 Jul 6:awag192. doi: 10.1093.
    PubMed    
    
    
    
15. MOSER T, Hitzl W, Lerda-Casaccia T, Unterhofer M, et al
    Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial.
    Brain. 2026;149:2286-94.
    PubMed     Abstract available
    
    
    
16. HAY CM, Mahjoub A, Vidarsson L, Soltanieh S, et al
    Retinal hyper-reflective foci link retinal and cortical pathology in paediatric multiple sclerosis.
    Brain. 2026 Jul 1:awag235. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2026
17. DUGAST E, Shah S, Vogel I, Loret A, et al
    Blood cytotoxic natural killer-like CD8 + CD94+ T cells migrate to the brain and predict multiple sclerosis severity.
    Brain. 2026 Jun 30:awag227. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. TUR C, Susin-Calle S, Otero-Romero S, Carvajal R, et al
    Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.
    Brain. 2026 Jun 10:awag047. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. ARLT FA, Miske R, Appeltshauser L, Zinnow V, et al
    Septin multimer autoantibodies in severe motor neuropathy mimicking lower motor neuron disease.
    Brain. 2026 Jun 8:awag183. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2026
20. TUR C
    High-efficacy therapy and progression independent of relapse and MRI activity in multiple sclerosis.
    Brain. 2026 May 28:awag175. doi: 10.1093.
    PubMed    
    
    
    
21. GRANBERG T
    The skull-meningeal axis: a new window into multiple sclerosis progression.
    Brain. 2026 May 28:awag177. doi: 10.1093.
    PubMed    
    
    
    
22. ARNABOLDI PM, Becker J, Nath A, Coyle PK, et al
    Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses.
    Brain. 2026 May 18:awag016. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. GEORGIEVA ZG, Howlett SK, Rainbow DB, Coppard V, et al
    Low-dose IL-2 fails to expand Tregs after alemtuzumab: insight into impaired immune tolerance in multiple sclerosis.
    Brain. 2026 May 13:awag171. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. DI LIBERTO G, Irani SR
    A chicken-or-egg dilemma resolved: autoantibodies initiate neurodegeneration.
    Brain. 2026;149:1423-1425.
    PubMed    
    
    
    
25. MONTINI F, Wing E, Herman M, Pittock SJ, et al
    The cascade to pathogenicity in autoantibody-mediated CNS diseases.
    Brain. 2026 May 4:awag158. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2026
26. SUICHI T, Misawa S, Ukita S, Shibuya K, et al
    The impact of the COVID-19 pandemic on the incidence and clinical profiles of Guillain-Barre syndrome in Japan.
    Brain. 2026 Apr 22:awag144. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. AGUZZI EA, Desai RA, Yang Z, Davies AL, et al
    A cause and protective treatment for acute and progressive disability and grey matter atrophy.
    Brain. 2026;149:1144-1152.
    PubMed     Abstract available
    
    
    March 2026
28. JACOBS BM, Vandebergh M, Maltby VE, Dobson R, et al
    Interplay between genetic and environmental risk factors in multiple sclerosis: what have we learned?
    Brain. 2026 Mar 27:awag111. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. LEAVITT VM
    Forget processing speed: cognitive changes in multiple sclerosis call for new measurement tools.
    Brain. 2026 Mar 16:awag107. doi: 10.1093.
    PubMed    
    
    
    
30. PAUL F
    Beyond autoantibodies: accelerating differential diagnosis in neuroimmunological diseases.
    Brain. 2026 Mar 11:awag093. doi: 10.1093.
    PubMed    
    
    
    
31. CORAZZOLLA G, Treaba CA, Mohammadian M, Brusaferri L, et al
    Evidence of skull bone translocator protein overexpression linked to multiple sclerosis progression.
    Brain. 2026 Mar 9:awag084. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. YOGESHWAR SM, Bartels F, Gruter T, Muniz-Castrillo S, et al
    Brain atrophy patterns in anti-IgLON5 disease.
    Brain. 2026;149:884-896.
    PubMed     Abstract available
    
    
    February 2026
33. ROLLOT F, Casey R, Kerbrat A, Edan G, et al
    Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.
    Brain. 2026 Feb 14:awag060. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. MURARO PA, De Matteis E, Scalfari A
    A tight match: comparing the effectiveness of immune reconstitution therapies for multiple sclerosis.
    Brain. 2026 Feb 3:awag044. doi: 10.1093.
    PubMed    
    
    
    January 2026
35. VILLAR LM
    The CD5-CK2-STAT3 axis in Th17 cell polarization: implications for multiple sclerosis.
    Brain. 2026;149:9-10.
    PubMed    
    
    
    December 2025
36. BELLANTI R, Keh RYS, Keddie S, Chou MKL, et al
    Plasma periaxin is a biomarker of peripheral nerve demyelination.
    Brain. 2025;148:4448-4460.
    PubMed     Abstract available
    
    
    
37. BRUMMER T, Fleischer V
    Beyond clinical labels: a molecular-structural framework for multiple sclerosis subtyping.
    Brain. 2025;148:4155-4157.
    PubMed    
    
    
    
38. WILLARD C, Puglisi L, Ravi D, Dmitrieva M, et al
    Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types.
    Brain. 2025 Dec 2:awaf331. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2025
39. LIN TY, McCormack B, Bacchetti A, Inserra M, et al
    Combining inter-eye differences enhances detection of optic nerve involvement in multiple sclerosis.
    Brain. 2025 Nov 26:awaf450. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. SUMOWSKI JF, Levy S, Katz Sand I, Brandstadter R, et al
    Cognition in multiple sclerosis within the modern diagnostic and treatment era.
    Brain. 2025 Nov 26:awaf446. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. BIGOTTE M, Groh AMR, Afanasiev E, Wong V, et al
    Cerebrospinal fluid-driven ependymal motile cilia defects are implicated in multiple sclerosis.
    Brain. 2025 Nov 24:awaf440. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. MACESKI AM, Benkert P, Einsiedler M, Schaedelin S, et al
    GFAP and NfL as predictors of disease progression and relapse activity in fingolimod-treated multiple sclerosis.
    Brain. 2025 Nov 14:awaf433. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2025
43. MASI G, Chen K, Bayer AC, Bayarri-Olmos R, et al
    IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology.
    Brain. 2025 Oct 28:awaf410. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. THEMISTOCLEOUS A, Middleton SJ, Dawes JM
    Understanding sensory abnormalities in fibromyalgia through autoantibodies.
    Brain. 2025 Oct 13:awaf384. doi: 10.1093.
    PubMed    
    
    
    
45. BELLANTI R, Iserte AC, Johnson CB, Goodfellow J, et al
    Enhanced adenoviral reactivity in Guillain-Barre syndrome after SARS-CoV-2 infection and vaccination.
    Brain. 2025 Oct 7:awaf376. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. MUKHERJEE T, McMurran CE, Holland J, Daruwalla C, et al
    Ageing and remyelination failure in people with multiple sclerosis.
    Brain. 2025 Oct 6:awaf373. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. ASHIKAWA Y, Itokazu T, Yamashita T
    Astrocyte regeneration via FGF8-DBX1 signalling facilitates recovery in neuromyelitis optica rats.
    Brain. 2025;148:3763-3777.
    PubMed     Abstract available
    
    
    September 2025
48. FURLAN R, Schaedelin S, Frederiksen JL, Watanabe M, et al
    Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.
    Brain. 2025 Sep 24:awaf345. doi: 10.1093.
    PubMed     Abstract available
    
    
    
49. FEINSTEIN A, Bar-Or A, Benedict RHB, Filippi M, et al
    Is multiple sclerosis-related depression different from depression in general? The data for and against.
    Brain. 2025 Sep 9:awaf319. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. ESSER D, Muller-Miny L, Heming M, Paunovic M, et al
    Activated alphabeta T and reduced mucosa-associated invariant T cells in LGI1- and CASPR2-encephalitis.
    Brain. 2025;148:3170-3183.
    PubMed     Abstract available
    
    
    August 2025
51. PAPE K, Hanuscheck N, Schmaul S, Kneilmann F, et al
    Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis.
    Brain. 2025 Aug 25:awaf268. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. RODRIGUES P, Frare JM, Ruviaro NA, Peres DS, et al
    Advanced oxidation protein products activated TRPA1 in a neuropathic multiple sclerosis model.
    Brain. 2025 Aug 17:awaf306. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. SGODZAI M, Kloster K, Karakaya H, Didhevar P, et al
    Tipping the balance: the PD1-axis as modulator in chronic inflammatory demyelinating polyneuropathy.
    Brain. 2025 Aug 16:awaf304. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. CHIEK TEOH CS, Dubey SG, Handel AE
    Rethinking corticosteroid therapy in autoimmune neurology.
    Brain. 2025 Aug 11:awaf292. doi: 10.1093.
    PubMed    
    
    
    
55. KALINCIK T, Sharmin S, Roos I, Freedman MS, et al
    Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis.
    Brain. 2025 Aug 4:awaf286. doi: 10.1093.
    PubMed     Abstract available
    
    
    
56. ABDELHAK A, Cordano C, Duncan GJ, Emberley K, et al
    Markers of axonal injury in blood and tissue triggered by acute and chronic demyelination.
    Brain. 2025;148:3011-3020.
    PubMed     Abstract available
    
    
    
57. NISHIGORI R, Hamatani M, Yoshitomi H, Kimura K, et al
    CD21lo B-cell subsets are recruited to the central nervous system in acute neuromyelitis optica.
    Brain. 2025;148:2995-3010.
    PubMed     Abstract available
    
    
    June 2025
58. CUNNIFFE NG
    Extending the role of neurofilament light in multiple sclerosis beyond measuring irreversible neurodegeneration.
    Brain. 2025 Jun 9:awaf224. doi: 10.1093.
    PubMed    
    
    
    
59. MAUDES E, Planaguma J, Marmolejo L, Radosevic M, et al
    Neuro-immunobiology and treatment assessment in a mouse model of anti-NMDAR encephalitis.
    Brain. 2025;148:2023-2037.
    PubMed     Abstract available
    
    
    May 2025
60. IRANI SR
    Models of autoantibody mediated diseases: actively nearing the human gold standard.
    Brain. 2025 May 23:awaf160. doi: 10.1093.
    PubMed    
    
    
    
61. FENG YF, Zeng ZK, Ni Y, Hu Y, et al
    Parvalbumin neurons mediate neurological phenotypes of anti-NMDAR encephalitis.
    Brain. 2025;148:1652-1664.
    PubMed     Abstract available
    
    
    
62. GIOVANNONI G, James L, Adeniran AA, Gold J, et al
    The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis.
    Brain. 2025 May 6:awaf170. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
63. NOBILE-ORAZIO E, Cocito D, Manganelli F, Fazio R, et al
    Rituximab versus placebo for chronic inflammatory demyelinating polyradiculoneuropathy: a randomized trial.
    Brain. 2025;148:1112-1121.
    PubMed     Abstract available
    
    
    March 2025
64. THOMMA RCM, Halstead SK, de Koning LC, Wiegers EEJA, et al
    Large-scale profiling of antibody reactivity to glycolipids in patients with Guillain-Barre syndrome.
    Brain. 2025 Mar 17:awaf102. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
65. GIOVANNONI G
    EBV-specific T-cell responses are telling us something important about multiple sclerosis.
    Brain. 2025 Jan 27:awaf027. doi: 10.1093.
    PubMed    
    
    
    December 2024
66. CHEN JQA, McNamara NB, Engelenburg HJ, Jongejan A, et al
    Distinct transcriptional changes distinguish efficient and poor remyelination in multiple sclerosis.
    Brain. 2024 Dec 24:awae414. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. ANDRODIAS G, Lunemann JD, Maillart E, Amato MP, et al
    De-escalating and discontinuing disease-modifying therapies in multiple sclerosis.
    Brain. 2024 Dec 21:awae409. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. COLES A
    A blood test to predict prognosis in multiple sclerosis?
    Brain. 2024;147:3969.
    PubMed    
    
    
    November 2024
69. SUN J, Guo M, Chai L, Xu S, et al
    Distinct virtual histology of grey matter atrophy in four neuroinflammatory diseases.
    Brain. 2024;147:3906-3917.
    PubMed     Abstract available
    
    
    September 2024
70. BERGNER CG, van der Meer F, Franz J, Vakrakou A, et al
    BCAS1-positive oligodendrocytes enable efficient cortical remyelination in multiple sclerosis.
    Brain. 2024 Sep 25:awae293. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
71. MONREAL E, Fernandez-Velasco JI, Alvarez-Lafuente R, Sainz de la Maza S, et al
    Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
    Brain. 2024 Aug 5:awae260. doi: 10.1093.
    PubMed     Abstract available
    
    
    
72. ZHAO M, Lynch DR, Irani SR
    Autoimmune 'secondary synaptopathies': do NMDAR antibodies cause a primary extra-synaptopathy?
    Brain. 2024;147:2601-2603.
    PubMed     Abstract available
    
    
    July 2024
73. FILIPPI M, Preziosa P, Barkhof F, Ciccarelli O, et al
    The ageing central nervous system in multiple sclerosis: the imaging perspective.
    Brain. 2024 Jul 24:awae251. doi: 10.1093.
    PubMed     Abstract available
    
    
    
74. HOLM RP, Wandall-Holm MF, Magyari M
    Multiple sclerosis in Denmark (1950-2023): mean age, sex distribution, incidence and prevalence.
    Brain. 2024 Jul 20:awae245. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. TAYLOR BV, Ponsonby AL, Stein M, Lucas R, et al
    Reply: Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size.
    Brain. 2024 Jul 19:awae246. doi: 10.1093.
    PubMed    
    
    
    
76. SCHNEIDER-HOHENDORF T, Wunsch C, Falk S, Raposo C, et al
    Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation.
    Brain. 2024 Jul 18:awae244. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. CORSTEN CEA, Wokke BHA, Smolders J
    Putative benefits of vitamin D supplements in multiple sclerosis out of reach due to sample size.
    Brain. 2024 Jul 16:awae238. doi: 10.1093.
    PubMed    
    
    
    May 2024
78. JAMET Z, Mergaux C, Meras M, Bouchet D, et al
    NMDA receptor autoantibodies primarily impair the extrasynaptic compartment.
    Brain. 2024 May 17:awae163. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2024
79. HUANG J, Tengvall K, Bomfim Lima I, Hedstrom AK, et al
    Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis.
    Brain. 2024 Apr 17:awae110. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. ARELLANO G, Loda E, Chen Y, Neef T, et al
    Interferon-gamma controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder.
    Brain. 2024;147:1344-1361.
    PubMed     Abstract available
    
    
    March 2024
81. MAINERO C, Miscioscia A, Treaba CA
    Cortical remyelination in multiple sclerosis: a target for disease monitoring and intervention.
    Brain. 2024 Mar 27:awae083. doi: 10.1093.
    PubMed    
    
    
    January 2024
82. HERRANZ E, Treaba CA, Barletta VT, Mehndiratta A, et al
    Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.
    Brain. 2024 Jan 30:awae030. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. LAZZAROTTO A, Hamzaoui M, Tonietto M, Dubessy AL, et al
    Time is myelin: early cortical myelin repair prevents atrophy and clinical progression in multiple sclerosis.
    Brain. 2024 Jan 24:awae024. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. BAGNATO F, Sati P, Hemond CC, Elliott C, et al
    Imaging chronic active lesions in multiple sclerosis: a consensus statement.
    Brain. 2024 Jan 16:awae013. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. SCHWAB N
    Transcriptomics reveals CSF cellular composition in multiple sclerosis but detects no viral RNA.
    Brain. 2024 Jan 5:awae006. doi: 10.1093.
    PubMed    
    
    
    
86. QIN C, Chen M, Dong MH, Yang S, et al
    Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
    Brain. 2024;147:163-176.
    PubMed     Abstract available
    
    
    
87. JAMANN H, Desu HL, Cui QL, Halaweh A, et al
    ALCAM on human oligodendrocytes mediates CD4 T cell adhesion.
    Brain. 2024;147:147-162.
    PubMed     Abstract available
    
    
    December 2023
88. MARZIALI LN, Hwang Y, Palmisano M, Cuenda A, et al
    p38gamma MAPK delays myelination and remyelination and is abundant in multiple sclerosis lesions.
    Brain. 2023 Dec 21:awad421. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. CALLEGARI I, Oechtering J, Schneider M, Perriot S, et al
    Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5.
    Brain. 2023 Dec 20:awad424. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. CREE BAC
    Herpes viral infection and the multiple sclerosis prodrome: is HHV-6A infection a second hit?
    Brain. 2023 Dec 18:awad418. doi: 10.1093.
    PubMed    
    
    
    
91. CLEAVER J, Jeffery K, Klenerman P, Lim M, et al
    The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity.
    Brain. 2023 Dec 13:awad419. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. BUTZKUEVEN H, Ponsonby AL, Stein MS, Lucas RM, et al
    Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.
    Brain. 2023 Dec 12:awad409. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. BAN M, Bredikhin D, Huang Y, Bonder MJ, et al
    Expression profiling of cerebrospinal fluid identifies dysregulated antiviral mechanisms in multiple sclerosis.
    Brain. 2023 Dec 1:awad404. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
94. KEDDIE S, Smyth D, Keh RYS, Chou MKL, et al
    Peripherin is a biomarker of axonal damage in peripheral nervous system disease.
    Brain. 2023;146:4562-4573.
    PubMed     Abstract available
    
    
    October 2023
95. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Human herpesvirus 6A and axonal injury before the clinical onset of multiple sclerosis.
    Brain. 2023 Oct 31:awad374. doi: 10.1093.
    PubMed     Abstract available
    
    
    
96. BERNARD HEALEY SA, Giovannoni G, Noyce A, Dobson R, et al
    Impact of multiple sclerosis risk alleles on the plasma proteome.
    Brain. 2023 Oct 18:awad363. doi: 10.1093.
    PubMed    
    
    
    
97. ALLEN NM, O'Rahelly M, Eymard B, Chouchane M, et al
    The emerging spectrum of fetal acetylcholine receptor antibody-related disorders (FARAD).
    Brain. 2023;146:4233-4246.
    PubMed     Abstract available
    
    
    September 2023
98. MATSUMOTO Y, Kaneko K, Takahashi T, Takai Y, et al
    Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Brain. 2023;146:3938-3948.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum